About Depixus
Depixus is a company based in Paris (France) founded in 2012 by Gordon Hamilton. Depixus has raised $34.52 million across 5 funding rounds from investors including Bpifrance, European Union and Arix Bioscience. Depixus offers products and services including MAGNA One. Depixus operates in a competitive market with competitors including Genomics, Seven Bridges Genomics, Ingenuity Systems, Eagle Genomics and BC Platforms, among others.
- Headquarter Paris, France
- Founders Gordon Hamilton
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$34.52 M (USD)
in 5 rounds
-
Latest Funding Round
$34.52 M (USD), Series A
Dec 15, 2021
-
Investors
Bpifrance
& 5 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Depixus
Depixus offers a comprehensive portfolio of products and services, including MAGNA One.
Platform for real-time analysis of biomolecular interactions in research.
People of Depixus
Unlock access to complete
Unlock access to complete
Funding Insights of Depixus
Depixus has successfully raised a total of $34.52M across 5 strategic funding rounds. The most recent funding activity was a Series A round of $34.52 million completed in December 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Depixus
Depixus has secured backing from 6 investors, including institutional and venture fund investors. Prominent investors backing the company include Bpifrance, European Union and Arix Bioscience.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investing in Life Sciences sectors like Healthcare and Biotechnology.
|
Locked | Locked | Locked | |
|
Investments in biotech startups are made by Arix Bioscience.
|
Locked | Locked | Locked | |
|
Government agency and accelerator focusing on innovative startups and SMEs
|
Locked | Locked | Locked |
Investor details for Depixus
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Depixus
Investment portfolio details for Depixus
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Depixus
Detailed financials for Depixus
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Depixus Comparisons
Peer comparison for Depixus
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Depixus
Depixus operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Genomics, Seven Bridges Genomics, Ingenuity Systems, Eagle Genomics and BC Platforms, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Genomic risk assessment and prevention platform is provided.
|
|
| Locked | Locked | Locked |
Cloud-based platform to analyze, store, and act on genomic data.
|
|
| Locked | Locked | Locked |
Genomic data is analyzed and interpreted via web-based applications.
|
|
| Locked | Locked | Locked |
Developer of cloud-based software solutions for genomic analysis
|
|
| Locked | Locked | Locked |
Platforms for genomic data analysis and management are provided.
|
Detailed competitors of Depixus
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Depixus
Complete news archive for Depixus
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Depixus
Depixus was founded in 2012 and raised its 1st funding round 4 years after it was founded.
Depixus is headquartered in Paris, France.
Gordon Hamilton is the current CEO of Depixus. They have also founded this company.
Depixus is a funded company, having raised a total of $34.52M across 5 funding rounds to date.
Depixus was founded in 2012 and is based in Paris, France, within the biotechnology sector. Solutions for single-molecule genetic and epigenetic sequencing are offered through the SIMDEQ platform technology. This technology, originally developed at École Normale Supérieure, relies on biophysical properties of DNA and RNA. Hairpin libraries are created from DNA and RNA, immobilized on magnetic beads, and manipulated by magnetic fields to enable zipping and unzipping processes for analysis.
Depixus's top competitors include Eagle Genomics, Ingenuity Systems and Envisagenics.
Depixus offers MAGNA One.
Depixus has 6 investors. Key investors include Bpifrance, European Union, Arix Bioscience, Lansdowne Partners, and Casdin Capital.